deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus trastuzumab plus vinorelbine
afatinib plus vinorelbine vs. trastuzumab plus vinorelbine 1 certainty unassessable+48% certainty unassessable+10%-